sequence semaglutide Peptide sequences and molecular structures of FDA approved GLP-1 RAs Semaglutide Peptide, CAS: 910463-68-2

"Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial." PLoS One 12.6 (2017): e0179538

Drug compounding is a well-established practice

Supports detoxification functions of the liver

Many products use synthetic fillers, artificial flavours, or "proprietary blends" that hide the actual amount of the active ingredient

They stimulate the production and release of melanin (melanogenesis) by melanocytes in skin and hair

Regional Trends North America accounted for the largest share of the global oral non-peptide GLP-1 receptor agonists market in 2025 and is expected to maintain its leadership throughout the forecast period